MiR-34a is Downregulated in Cis-diamminedichloroplatinum Treated Sinonasal Squamous Cell Carcinoma Patients with Poor Prognosis

Overview

Journal Cancer Sci

Specialty Oncology

Date 2012 May 26

PMID 22624980

Citations 15

Authors

Takenori Ogawa

Yuriko Saiki

Kiyoto Shiga

Na Chen

Shinichi Fukushige

Makoto Sunamura

Hiroki Nagase

Sho Hashimoto

Kazuto Matsuura

Shigeru Saijo

Toshimitsu Kobayashi

Akira Horii

Affiliations

Soon will be listed here.

Abstract

For the purpose of analyzing mechanisms related to the cis-diamminedichloroplatinum resistance in head and neck squamous cell carcinoma, we analyzed RPMI2650 and its derived previously established cis-diamminedichloroplatinum resistant cell line RPMI2650CR. To identify resistant phenotype-related microRNAs, we compared microRNA expressions between RPMI2650CR and RPMI2650 by microarray. One of the microRNAs as downregulated, miR-34a, was further investigated. Decreased expression of miR-34a in RPMI2650CR was confirmed by quantitative reverse transcription-polymerase chain reaction, but introduction of the miR-34a precursor into RPMI2650CR or the inhibitor of miR-34a into RPMI2650 did not change cis-diamminedichloroplatinum sensitivities. However, 24 patients with sinonasal squamous cell carcinomas treated with intra-arterial infusion of cis-diamminedichloroplatinum showed a significant association between decreased expression of miR-34a and poor disease specific survival (P = 0.0015), poor disease free survival (P = 0.0019), and poor local control rates (P = 0.017) (median follow-up period: 53 months). Furthermore, multivariate analyses demonstrated significant associations between miR-34a expression and the hazard ratios of disease free survival at 0.005 (95% confidence interval [CI] 0.00-0.29, P = 0.011) and local control rate at 0.008 (95% CI 0.00-0.44, P = 0.019), although other parameters such as age, gender, treatment method, T and N stages did not show any similar association. These results strongly suggest that miR-34a expression can be an independent prognostic biomarker in patients with sinonasal squamous cell carcinoma who are undergoing treatment with cis-diamminedichloroplatinum.

Citing Articles

AGO2-RIP-Seq reveals miR-34/miR-449 cluster targetome in sinonasal cancers.

Tomasetti M, Monaco F, Rubini C, Rossato M, De Quattro C, Beltrami C PLoS One. 2024; 19(1):e0295997.

PMID: 38215077 PMC: 10786392. DOI: 10.1371/journal.pone.0295997.

The Potential microRNA Prognostic Signature in HNSCCs: A Systematic Review.

Dioguardi M, Spirito F, Iacovelli G, Sovereto D, Laneve E, Laino L Noncoding RNA. 2023; 9(5).

PMID: 37736900 PMC: 10514860. DOI: 10.3390/ncrna9050054.

Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.

Jayaraj R, Polpaya K, Kunale M, Kodiveri Muthukaliannan G, Shetty S, Baxi S Genes (Basel). 2022; 13(12).

PMID: 36553594 PMC: 9777665. DOI: 10.3390/genes13122325.

Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Thomaidou A, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis C, Zoumpourlis V Int J Mol Sci. 2022; 23(15).

PMID: 35897831 PMC: 9367895. DOI: 10.3390/ijms23158257.

Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in laryngeal squamous cell cancer.

Huang Y, Gu M, Tang Y, Sun Z, Luo J, Li Z Cancer Cell Int. 2021; 21(1):316.

PMID: 34158050 PMC: 8220842. DOI: 10.1186/s12935-021-02021-8.

References

Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A . miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010; 70(5):1793-803. DOI: 10.1158/0008-5472.CAN-09-3112. View

Rosenberg B, VANCAMP L, Trosko J, Mansour V . Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191):385-6. DOI: 10.1038/222385a0. View

Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L . MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009; 4(8):e6816. PMC: 2729376. DOI: 10.1371/journal.pone.0006816. View

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

Gallardo E, Navarro A, Vinolas N, Marrades R, Diaz T, Gel B . miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009; 30(11):1903-9. DOI: 10.1093/carcin/bgp219. View

Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon J . Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res. 2011; 17(9):3029-38. DOI: 10.1158/1078-0432.CCR-10-2532. View

Weeraratne S, Amani V, Neiss A, Teider N, Scott D, Pomeroy S . miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2010; 13(2):165-75. PMC: 3064629. DOI: 10.1093/neuonc/noq179. View

Ogawa T, Shiga K, Hashimoto S, Kobayashi T, Horii A, Furukawa T . APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line. Biochem Biophys Res Commun. 2003; 306(2):537-43. DOI: 10.1016/s0006-291x(03)00995-1. View

Ogawa T, Ogawa K, Shiga K, Furukawa T, Nagase H, Hashimoto S . Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2010; 267(10):1599-606. DOI: 10.1007/s00405-010-1257-4. View

10.

Andrews P, Howell S . Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990; 2(2):35-43. View

11.

Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M . miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012; 103(9):1737-43. PMC: 7659179. DOI: 10.1111/j.1349-7006.2012.02338.x. View

12.

Ogawa T, Furukawa T, Shiga K, Hashimoto S, Ogawa K, Kobayashi T . A cDNA microarray analysis identifies 52 genes associated with cis-diamminedichloroplatinum susceptibility in head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol. 2009; 267(1):123-9. DOI: 10.1007/s00405-009-0976-x. View

13.

Kumamoto K, Spillare E, Fujita K, Horikawa I, Yamashita T, Appella E . Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 2008; 68(9):3193-203. PMC: 2440635. DOI: 10.1158/0008-5472.CAN-07-2780. View

14.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

15.

Chang T, Wentzel E, Kent O, Ramachandran K, Mullendore M, Lee K . Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007; 26(5):745-52. PMC: 1939978. DOI: 10.1016/j.molcel.2007.05.010. View

16.

Ma L, Ronai A, Riede U, Kohler G . Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas. J Cancer Res Clin Oncol. 1998; 124(7):389-96. DOI: 10.1007/s004320050188. View

17.

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

18.

Shiga K, Yokoyama J, Hashimoto S, Saijo S, Tateda M, Ogawa T . Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma. Otolaryngol Head Neck Surg. 2007; 136(6):1003-9. DOI: 10.1016/j.otohns.2006.12.018. View

19.

Forastiere A, Goepfert H, Maor M, Pajak T, Weber R, Morrison W . Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22):2091-8. DOI: 10.1056/NEJMoa031317. View

20.

Pogribny I, Filkowski J, Tryndyak V, Golubov A, Shpyleva S, Kovalchuk O . Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010; 127(8):1785-94. DOI: 10.1002/ijc.25191. View